11. Juni 2019Prostatakarzinom

ASCO 2019: Bei mHSPC ist eine zeitnahe Zweifach-Kombi-Therapie entscheidend

OA Dr. Franz Stoiber, Abteilung für Urologie und Andrologie, Salzkammergut-Klinikum Vöcklabruck, fasst die Prostatakarzinom-Learnings vom ASCO 2019 zusammen, darunter Studien mit Apalutamid bzw. Enzalutamid bei mHSPC, die jeweils als Zusatz zu einer Standardtherapie das Outcome verbesserten.

Abstracts, die im Video diskutiert werden:

Abstract  5006
First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
Kim N. Chi

Abstract  LBA2
Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.
Christopher Sweeney

Abstract  5000
Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).
Karim Fizazi

Abstract  5003
Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC.
Kim N. Chi

Abstract  5007
Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.
Bertrand F. Tombal

Abstract  5008
Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
Michael J. Morris